Hematological toxicity evaluation of the PARP inhibitor- fluzopril in a wide population of ovarian cancer based on active monitoring mode

Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2023
This article has no abstract
Epistemonikos ID: 09f00bcd8b52640c6addb05e0826bd036db3762b
First added on: Apr 08, 2025